AR061500A1 - Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes - Google Patents

Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes

Info

Publication number
AR061500A1
AR061500A1 ARP070102661A ARP070102661A AR061500A1 AR 061500 A1 AR061500 A1 AR 061500A1 AR P070102661 A ARP070102661 A AR P070102661A AR P070102661 A ARP070102661 A AR P070102661A AR 061500 A1 AR061500 A1 AR 061500A1
Authority
AR
Argentina
Prior art keywords
diabetes
diabetic
hyperglucemia
compound
control
Prior art date
Application number
ARP070102661A
Other languages
English (en)
Spanish (es)
Original Assignee
Indigene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indigene Pharmaceuticals Inc filed Critical Indigene Pharmaceuticals Inc
Publication of AR061500A1 publication Critical patent/AR061500A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP070102661A 2006-06-16 2007-06-15 Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes AR061500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81425006P 2006-06-16 2006-06-16

Publications (1)

Publication Number Publication Date
AR061500A1 true AR061500A1 (es) 2008-09-03

Family

ID=38669506

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102661A AR061500A1 (es) 2006-06-16 2007-06-15 Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes

Country Status (10)

Country Link
US (1) US7973073B2 (enExample)
EP (1) EP2046773A1 (enExample)
JP (1) JP2009541220A (enExample)
CN (1) CN101522658A (enExample)
AR (1) AR061500A1 (enExample)
CA (1) CA2691775A1 (enExample)
CL (1) CL2007001759A1 (enExample)
IL (1) IL195959A0 (enExample)
TW (1) TW200816986A (enExample)
WO (1) WO2007149313A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
WO2008067403A2 (en) * 2006-11-28 2008-06-05 Encore Health Llc Presbyopia treatment by lens alteration
US8102027B2 (en) * 2007-08-21 2012-01-24 Broadcom Corporation IC package sacrificial structures for crack propagation confinement
WO2009111037A2 (en) * 2008-03-04 2009-09-11 Indigene Pharmaceuticals Inc. Compositions and methods for treating nos-associated diseases
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
ES2450148T3 (es) * 2008-06-26 2014-03-24 Laboratorios Silanes, S.A. De C.V. Una nueva sal de glicinato de metformina para el control de la glucosa en sangre
US20100099751A1 (en) * 2008-10-21 2010-04-22 Al-Mulla Fahd Method of treating diabetes-related vascular complications
WO2010047717A1 (en) * 2008-10-24 2010-04-29 Biolink Life Sciences, Inc. Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
EP2442645B1 (en) 2009-06-15 2014-08-27 Encore Health, Llc Choline esters
DK2442647T3 (en) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivatives thereof, and the uses of these
WO2011130719A2 (en) 2010-04-15 2011-10-20 The Regents Of The University Of Michigan A biosynthetic pathway for heterologous expression of a nonribosomal peptide synthetase drug and analogs
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8440723B2 (en) * 2011-05-11 2013-05-14 Banavara L. Mylari Metformin salts of salicylic acid and its congeners
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes
WO2015022613A1 (en) * 2013-08-11 2015-02-19 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
CN106455563A (zh) 2014-03-03 2017-02-22 安可视觉公司 硫辛酸胆碱酯组合物及使用方法
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
EP3157936B1 (en) 2014-06-18 2018-10-17 Thetis Pharmaceuticals LLC Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
KR102405239B1 (ko) * 2017-11-17 2022-06-08 셀릭스 바이오 프라이빗 리미티드 눈 질환 및 피부 질환의 치료를 위한 화합물, 조성물 및 방법
AU2018367909B2 (en) * 2017-11-17 2022-03-10 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
CN110037998A (zh) * 2018-01-16 2019-07-23 镇学初 二甲双胍盐在治疗脑梗死中的用途
CN110294738A (zh) * 2019-07-22 2019-10-01 通化师范学院 硫辛酸衍生物及其制备方法和用途
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids

Also Published As

Publication number Publication date
CL2007001759A1 (es) 2008-10-24
TW200816986A (en) 2008-04-16
CN101522658A (zh) 2009-09-02
EP2046773A1 (en) 2009-04-15
IL195959A0 (en) 2009-09-22
JP2009541220A (ja) 2009-11-26
US7973073B2 (en) 2011-07-05
WO2007149313A1 (en) 2007-12-27
CA2691775A1 (en) 2007-12-27
US20070293562A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
AR061500A1 (es) Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes
Zhao et al. Hydrogen sulfide (H 2 S) releasing agents: chemistry and biological applications
Park et al. Synthesis and evaluation of phosphorodithioate-based hydrogen sulfide donors
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
BR122017021516B8 (pt) processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
CL2004000969A1 (es) Compuestos derivados de alquilarilo; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de la obesidad y trastornos relacionados.
DE602004015970D1 (de) Verfahren zur überwachung des blutflusses und der metabolischen aufnahme in gewebe mit radioaktiv markierter alkansäure
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
BRPI0413276A (pt) derivado de insulina, complexo de zinco do mesmo, composição farmacêutica, e, método para tratar diabete em um paciente
BRPI1007622B8 (pt) Composto, composição, método não terapêutico para controlar um nematódeo parasítico e semente revestida
PE20091843A1 (es) Inhibidores de catepsina c
ECSP099330A (es) Compuesto de indol
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
CO6190603A2 (es) Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
AR047085A1 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad
PE20191205A1 (es) Composiciones farmaceuticas que contienen insulina
BRPI0514448A (pt) derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
AR112353A1 (es) Compuesto de insulina acilada
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
BR112013009631B8 (pt) Método de remover seletivamente arsênio de material de sulfeto contendo arsênio
BRPI1006006A8 (pt) Compostos, composição fungicida e método para o controle de fungos fitopatogênicos de culturas

Legal Events

Date Code Title Description
FB Suspension of granting procedure